Search the Health Library
Get the facts on diseases, conditions, tests and procedures.
I Want To...
Find a Doctor
Find a doctor at The Johns Hopkins Hospital, Johns Hopkins Bayview Medical Center or Johns Hopkins Community Physicians.
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
Genome Code Cracked for Most Common Form of Pediatric Brain Cancer - 12/16/2010
Genome Code Cracked for Most Common Form of Pediatric Brain Cancer
Scientists at the Johns Hopkins Kimmel Cancer Center have deciphered the genetic code for medulloblastoma, the most common pediatric brain cancer and a leading killer of children with cancer. The genetic "map" is believed to be the first reported of a pediatric cancer genome and is published online in the Dec. 16 issue of Science Express.
Notably, the findings show that children with medulloblastoma have five- to tenfold fewer cancer-linked alterations in their genomes compared with their adult counterparts, the scientists say.
"These analyses clearly show that genetic changes in pediatric cancers are remarkably different from adult tumors. With fewer alterations, the hope is that it may be easier to use the information to develop new therapies for them," says Victor Velculescu, M.D., Ph.D., associate professor of oncology at the Johns Hopkins Kimmel Cancer Center.
"We now know what many pieces of the medulloblastoma puzzle are," adds Bert
Vogelstein, M.D., Clayton Professor of Oncology and co-director of the Ludwig Center at Johns Hopkins. "Now, we must figure out how to put the puzzle together and zero in on parts of the puzzle to develop new therapies. This is what scientists will be focused on for the next decade."
The Johns Hopkins team used automated tools to sequence hundreds of millions of individual chemicals called nucleotides, which pair together in a preprogrammed fashion to build DNA and, in turn, a genome. Combinations of these nucleotide letters form genes, which provide instructions that guide cell activity. Alterations in the nucleotides, called mutations, can create coding errors that transform a normal cell into a cancerous one. The scientists at Johns Hopkins have previously mapped genome sequences for pancreatic, adult brain, breast and colon cancers with similar methods.
For the study, scientists sequenced nearly all protein-encoding genes in 22 samples of pediatric medulloblastoma and compared these sequences with normal DNA from each patient to identify tumor-specific changes or mutations. Each tumor sample had an average of 11 mutations. There were 225 mutations in all.
Then, the investigators searched through a second set of 66 medulloblastomas, including some samples from adults, to find how these mutations altered the proteins made by the genes.
The team found that most of the mutations congregate within a few gene families or pathways. The most prevalent pathway ordered the way long strands of DNA, that make up chromosomes, are twisted and shaped into dense packets that open and close depending on when genes need to be activated. Such a process is regulated by chemicals that operate outside of genes, termed "epigenetic" by scientists.
Within the epigenetic pathway, two commonly mutated genes were both involved in how molecules called histones wrap around DNA.
"These epigenetic changes may be more important than we thought in childhood cancers," says Will Parsons, M.D., Ph.D., formerly of Johns Hopkins and now an assistant professor at Texas Children's Cancer Center and Baylor College of Medicine.
Mutations in MLL2 and MLL3 were identified in 16 percent of the entire set of 88 medulloblastoma samples. Add to this three other epigenetic alterations found by the scientists in the genome scan, and the total set accounts for 20 percent of mutations in all the brain cancer samples.
Second to epigenetic pathways were gene mutations in pathways such as Hedgehog and Wnt that control tissue and organ development in humans and other animals. Both pathways have previously been linked to childhood medulloblastoma.
Cancer is the leading cause of death by disease in children in the United States, and more children die of brain tumors than any other type of cancer. Medulloblastoma is the most common malignant brain tumor in children, occurring in about 400 children per year in the United States.
"It's a particular challenge to treat children with brain cancer," says Parsons, "because our most effective treatments, surgery and radiation therapy, can cause significant side effects, including cognitive disabilities and hormone abnormalities. For our youngest patients, the effects can be potentially devastating."
Yet Parsons is encouraged by the study's findings. "As oncologists, we're working to understand how specific genetic changes found in patients' cancers should guide their treatment. Any information that allows us to understand a patient's prognosis or provides clues about therapies that might work best in a patient is crucial and will help us provide better care."
The study was funded primarily through the National Cancer Institute's Cancer Genome Characterization Initiative (CGCI) as well as The Virginia and D.K. Ludwig Fund for Cancer Research, Alex's Lemonade Stand Foundation, the American Brain Tumor Association, the Brain Tumor Research Fund at Johns Hopkins, the Hoglund Foundation, the Ready or Not Foundation, the Children's Brain Tumor Foundation, The Pediatric Brain Tumor Foundation Institute, an AACR Stand Up To Cancer-Dream Team Translational Cancer Research Grant, the Johns Hopkins Sommer Scholar Program, the National Institutes of Health, the National Science Foundation, and Department of Defense. Parsons is a Graham Cancer Research Scholar at the Texas Children's Cancer Center.
Additional scientists involved in the study are Meng Li, Xiaosong Zhang, Siân Jones, Rebecca J. Leary, Jimmy Cheng-Ho Lin, Simina M. Boca, Hannah Carter, Josue Samayoa, Chetan Bettegowda, Gary L. Gallia, George I. Jallo, Zev A. Binder, Peter C.
Burger, Gregory J. Riggins, Rachel Karchin, Nick Papadopoulos, and Kenneth W. Kinzler from Johns Hopkins; Yuri Nikolsky from GeneGo Inc.; James Hartigan and Doug R. Smith from Beckman Coulter Genomics Inc.; Daniela S. Gerhard from the National Cancer Institute; Daniel W. Fults from the University of Utah; Scott VandenBerg from the University of California, San Diego; Mitchel S. Berger from the University of California, San Francisco; Suely Kazue Nagahashi Marie, Sueli Mieko Oba Shinjo, and Carlos Clara from the University of Sao Paolo and Barretos Cancer Hospital, Sao Paolo, Brazil; Peter C. Phillips, Jane E. Minturn, Jaclyn A. Biegel, Alexander R. Judkins, Adam C. Resnick, Phillip B. Storm, and Tom Curran from the Children's Hospital of Philadelphia; Yiping He, B. Ahmed Rasheed, Henry S. Friedman, Stephen T. Keir, Roger McLendon, Darell D. Bigner and Hai Yan from Duke University; Paul A. Northcott and Michael D.
Taylor from the University of Toronto; and Giovanni Parmigiani from the Dana Farber Cancer Institute.
Under licensing agreements between the Johns Hopkins University and Beckman Coulter, Vogelstein, Kenneth Kinzler and Velculescu are entitled to a share of royalties received by the university on sales of products related to research described in this paper. Nickolas Papadopoulos, Vogelstein, Kinzler and Velculescu are co-founders of Inostics and Personal Genome Diagnostics and are members of their scientific advisory boards. Papadopoulos, Vogelstein, Kinzler and Velculescu own Inostics and Personal Genome Diagnostics stock, which is subject to certain restrictions under university policy. The terms of these arrangements are managed by The Johns Hopkins University in accordance with its conflict-of-interest policies.
On the Web:
For the Media
Johns Hopkins Kimmel Cancer Center
Office of Public Affairs
Media Contact: Vanessa Wasta